8-cyclopentyl-1,3-dimethylxanthine has been researched along with Central Nervous System Diseases in 1 studies
8-cyclopentyl-1,3-dimethylxanthine: prolongs epileptic seizures in rats
Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dall'Igna, OP | 1 |
| Porciúncula, LO | 1 |
| Souza, DO | 1 |
| Cunha, RA | 1 |
| Lara, DR | 1 |
| Dall'lgna, OP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401] | 24 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 8-cyclopentyl-1,3-dimethylxanthine and Central Nervous System Diseases
| Article | Year |
|---|---|
Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity.
Topics: Adenosine A2 Receptor Antagonists; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Caffein | 2003 |